HUTCHMED (China) Future Growth
Future criteria checks 4/6
HUTCHMED (China) is forecast to grow earnings and revenue by 47.9% and 18% per annum respectively. EPS is expected to grow by 105.7% per annum. Return on equity is forecast to be 8.9% in 3 years.
Key information
47.9%
Earnings growth rate
105.7%
EPS growth rate
| Pharmaceuticals earnings growth | 10.8% |
| Revenue growth rate | 18.0% |
| Future return on equity | 8.9% |
| Analyst coverage | Good |
| Last updated | 22 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 990 | 116 | 63 | 106 | 18 |
| 12/31/2025 | 808 | 37 | -30 | 15 | 22 |
| 12/31/2024 | 670 | -38 | -131 | -58 | 22 |
| 6/30/2024 | 611 | -42 | -65 | -47 | N/A |
| 3/31/2024 | 724 | 29 | 61 | 86 | N/A |
| 12/31/2023 | 838 | 101 | 187 | 219 | N/A |
| 9/30/2023 | 798 | 36 | 95 | 133 | N/A |
| 6/30/2023 | 757 | -29 | 2 | 48 | N/A |
| 3/31/2023 | 592 | -195 | -151 | -110 | N/A |
| 12/31/2022 | 426 | -361 | -305 | -269 | N/A |
| 9/30/2022 | 414 | -308 | -276 | -246 | N/A |
| 6/30/2022 | 401 | -255 | -246 | -223 | N/A |
| 3/31/2022 | 376 | -235 | -245 | -227 | N/A |
| 12/31/2021 | 356 | -195 | -221 | -204 | N/A |
| 9/30/2021 | 317 | -187 | -169 | -155 | N/A |
| 6/30/2021 | 279 | -178 | -118 | -105 | N/A |
| 3/31/2021 | 258 | -151 | -95 | -83 | N/A |
| 12/31/2020 | 228 | -126 | -70 | -62 | N/A |
| 9/30/2020 | 221 | -117 | -72 | -63 | N/A |
| 6/30/2020 | 209 | -110 | -88 | -79 | N/A |
| 3/31/2020 | 204 | -102 | -63 | -54 | N/A |
| 12/31/2019 | 205 | -106 | -89 | -81 | N/A |
| 9/30/2019 | 205 | -93 | -86 | -77 | N/A |
| 6/30/2019 | 214 | -87 | -52 | -44 | N/A |
| 3/31/2019 | 214 | -83 | -37 | -31 | N/A |
| 12/31/2018 | 214 | -75 | -39 | -33 | N/A |
| 9/30/2018 | 218 | -72 | -38 | -33 | N/A |
| 6/30/2018 | 217 | -61 | -51 | -47 | N/A |
| 3/31/2018 | 230 | -39 | N/A | -49 | N/A |
| 12/31/2017 | 241 | -27 | N/A | -9 | N/A |
| 9/30/2017 | 240 | -7 | N/A | -4 | N/A |
| 6/30/2017 | 238 | 13 | N/A | 1 | N/A |
| 3/31/2017 | 227 | 12 | N/A | -4 | N/A |
| 12/31/2016 | 216 | 12 | N/A | -10 | N/A |
| 9/30/2016 | 200 | 38 | N/A | 2 | N/A |
| 6/30/2016 | 200 | -8 | N/A | -1 | N/A |
| 3/31/2016 | 189 | -22 | N/A | -5 | N/A |
| 12/31/2015 | 178 | -35 | N/A | -9 | N/A |
| 9/30/2015 | 168 | -80 | N/A | -11 | N/A |
| 6/30/2015 | 139 | -66 | N/A | -6 | N/A |
| 3/31/2015 | 113 | -50 | N/A | 1 | N/A |
| 12/31/2014 | 87 | -35 | N/A | 8 | N/A |
| 9/30/2014 | 72 | -20 | N/A | 11 | N/A |
| 6/30/2014 | 59 | 7 | N/A | 21 | N/A |
| 3/31/2014 | 52 | 8 | N/A | 13 | N/A |
| 12/31/2013 | 37 | 26 | N/A | 5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 13 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: 13 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 13 is expected to become profitable in the next 3 years.
Revenue vs Market: 13's revenue (18% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 13's revenue (18% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 13's Return on Equity is forecast to be low in 3 years time (8.9%).